ArticleInternational journal of molecular sciences2021
Gut Microbiota-Derived l-Histidine/Imidazole Propionate Axis Fights against the Radiation-Induced Cardiopulmonary Injury.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- From Host-Microbiome Symbiosis to Clinical Translation: A Gut Microbiome Perspective on Radiation Enteritis.International journal of biological sciences · 2026Review
- Gut-lung axis in radiation-induced lung injury: mechanisms and interventions.Frontiers in immunology · 2026Review
- Gut microbiota and microbiota-derived metabolites in radiation-induced injury: mechanisms and therapeutic opportunities.Frontiers in microbiology · 2026Review
- Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies.Gut microbes · 2025Review
- An Update on Dynamic Changes in Cytokine Expression and Dysbiosis Due to Radiation Combined Injury.International journal of molecular sciences · 2025Review
- Targeting gut microbiota and metabolites in cancer radiotherapy.Clinical and translational medicine · 2025Review
- The Role of Gut Microbiota and Its Metabolites in Mitigating Radiation Damage.Microorganisms · 2025Review
- Article
- Mechanisms of exercise in preventing cardiovascular diseases: Insights from gut microbiota characteristics in pathological states of cardiovascular diseases.Reviews in endocrine & metabolic disorders · 2025Review
- Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS.BMC gastroenterology · 2025Article
- Is Deuterium Sequestering by Reactive Carbon Atoms an Important Mechanism to Reduce Deuterium Content in Biological Water?FASEB bioAdvances · 2025Review
- The oral-gut microbiota axis: a link in cardiometabolic diseases.NPJ biofilms and microbiomes · 2025Review
- The cancer microbiome.Advances in clinical chemistry · 2025Review
- Differences in risk factors for mortality between T2N1M0 and T3N0M0 lobular breast cancer patients: a comparative study.Frontiers in pharmacology · 2025Article
- Radiation-induced injury and the gut microbiota: insights from a microbial perspective.Therapeutic advances in gastroenterology · 2025Review
- Histopathological Evaluation of Radioprotective Effects: Selenium Nanoparticles Protect Lung Tissue from Radiation Damage.Advanced biomedical research · 2025Article
- Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes.Frontiers in microbiology · 2025Review
- Review
- Oral administration of probiotic spore ghosts for efficient attenuation of radiation-induced intestinal injury.Journal of nanobiotechnology · 2024Article
- Radiation injury and gut microbiota-based treatment.Protein & cell · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Radiation-induced cardiopulmonary injuries are the most common and intractable side effects that are entwined with radiotherapy for thorax cancers. However, the therapeutic options for such complications have yielded disappointing results in clinical applications. Here, we reported that gut microbiota-derived l-Histidine and its secondary metabolite imidazole propionate (ImP) fought against radiation-induced cardiopulmonary injury in an entiric flora-dependent manner in mouse models. Local chest irradiation decreased the level of l-Histidine in fecal pellets, which was increased following fecal microbiota transplantation. l-Histidine replenishment via an oral route retarded the pathological process of lung and heart tissues and improved lung respiratory and heart systolic function following radiation exposure. l-Histidine preserved the gut bacterial taxonomic proportions shifted by total chest irradiation but failed to perform radioprotection in gut microbiota-deleted mice. ImP, the downstream metabolite of l-Histidine, accumulated in peripheral blood and lung tissues following l-Histidine replenishment and protected against radiation-induced lung and heart toxicity. Orally gavaged ImP could not enter into the circulatory system in mice through an antibiotic cocktail treatment. Importantly, ImP inhibited pyroptosis to nudge lung cell proliferation after radiation challenge. Together, our findings pave a novel method of protection against cardiopulmonary complications intertwined with radiotherapy in pre-clinical settings and underpin the idea that gut microbiota-produced l-Histidine and ImP are promising radioprotective agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.